New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape.
暂无分享,去创建一个
Deepak Mittal | R. Schreiber | M. Smyth | D. Mittal | M. Gubin | Robert D Schreiber | Mark J Smyth | Matthew M Gubin
[1] M. Stratton,et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Michael R. Green,et al. Erratum: Depleting tumor-specific Tregs at a single site eradicates disseminated tumors (Journal of Clinical Investigation (2013) 123:11 (4980) DOI:10.1172/JCI73340) , 2013 .
[3] R. Noelle,et al. B7 family checkpoint regulators in immune regulation and disease. , 2013, Trends in immunology.
[4] Z. Yao,et al. Immune microenvironment profiles of tumor immune equilibrium and immune escape states of mouse sarcoma. , 2013, Cancer letters.
[5] R. Schwabe,et al. The Microbiome and Cancer , 2021, Gut Feelings.
[6] S. Lowe,et al. p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells , 2013, The Journal of experimental medicine.
[7] H. Schreiber,et al. Innate and adaptive immune cells in the tumor microenvironment , 2013, Nature Immunology.
[8] G. Dranoff. Immunotherapy at Large: Balancing tumor immunity and inflammatory pathology , 2013, Nature Medicine.
[9] M. Smyth,et al. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors , 2013, Proceedings of the National Academy of Sciences.
[10] Jérôme Galon,et al. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. , 2013, Immunity.
[11] C. Horak,et al. Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.
[12] Jens-Peter Volkmer,et al. Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies , 2013, Science.
[13] Bart Spiessens,et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] E. Gilson,et al. TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells , 2013, Nature Cell Biology.
[15] Michael R. Green,et al. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. , 2013, The Journal of clinical investigation.
[16] Jimmy Lin,et al. Mining Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred Tumor-reactive T cells , 2013, Nature Medicine.
[17] J. Galon,et al. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. , 2013, Current opinion in immunology.
[18] W. Chng,et al. ATM-dependent spontaneous regression of early Eμ-myc-induced murine B-cell leukemia depends on natural killer and T cells. , 2013, Blood.
[19] L. Zender,et al. T-helper-1-cell cytokines drive cancer into senescence , 2013, Nature.
[20] H. Moch,et al. NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma. , 2013, Cancer immunity.
[21] C. Datz,et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth , 2012, Nature.
[22] Ming Li,et al. An Immunosurveillance Mechanism Controls Cancer Cell Ploidy , 2012, Science.
[23] S. Gasser,et al. Ras Activation Induces Expression of Raet1 Family NK Receptor Ligands , 2012, The Journal of Immunology.
[24] R. Schreiber,et al. Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state. , 2012, Cancer research.
[25] D. Olive,et al. B and T Lymphocyte Attenuator Mediates Inhibition of Tumor-Reactive CD8+ T Cells in Patients After Allogeneic Stem Cell Transplantation , 2012, The Journal of Immunology.
[26] C. Drake,et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.
[27] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[28] M. Smyth,et al. CD73: a potent suppressor of antitumor immune responses. , 2012, Trends in immunology.
[29] Stefan Michiels,et al. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Mark J. Smyth,et al. Cancer immunoediting by the innate immune system in the absence of adaptive immunity , 2012, The Journal of experimental medicine.
[31] Jens-Peter Volkmer,et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors , 2012, Proceedings of the National Academy of Sciences.
[32] G. Dranoff,et al. Combining immunotherapy and targeted therapies in cancer treatment , 2012, Nature Reviews Cancer.
[33] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[34] J. Castle,et al. Exploiting the mutanome for tumor vaccination. , 2012, Cancer research.
[35] Ornella Pagliano,et al. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. , 2012, Cancer research.
[36] E. Mardis,et al. Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting , 2012, Nature.
[37] T. Jacks,et al. Expression of tumour-specific antigens underlies cancer immunoediting , 2011, Nature.
[38] M. Roizen,et al. Hallmarks of Cancer: The Next Generation , 2012 .
[39] Rui-Ru Ji,et al. An immune-active tumor microenvironment favors clinical response to ipilimumab , 2012, Cancer Immunology, Immunotherapy.
[40] George Coukos,et al. Cancer immunotherapy comes of age , 2011, Nature.
[41] T. Luedde,et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development , 2011, Nature.
[42] F. Marincola,et al. Molecular Insights on the Peripheral and Intratumoral Effects of Systemic High-Dose rIL-2 (Aldesleukin) Administration for the Treatment of Metastatic Melanoma , 2011, Clinical Cancer Research.
[43] K. Murphy,et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells , 2011, The Journal of experimental medicine.
[44] R. Schreiber,et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors , 2011, The Journal of experimental medicine.
[45] Axel Benner,et al. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. , 2011, Cancer research.
[46] Eric C. Sorenson,et al. Imatinib Potentiates Anti-tumor T Cell Responses in Gastrointestinal Stromal Tumor through the Inhibition of Ido Nih Public Access Author Manuscript , 2022 .
[47] L. Old,et al. Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™ , 2011, Cancer Immunology, Immunotherapy.
[48] Jan Tavernier,et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors , 2011, Nature Medicine.
[49] Yan Zheng,et al. Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. , 2011, Current opinion in immunology.
[50] R. Schreiber,et al. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.
[51] R. Schreiber,et al. Natural innate and adaptive immunity to cancer. , 2011, Annual review of immunology.
[52] David C. Gondek,et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses , 2011, The Journal of experimental medicine.
[53] J. Galon,et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. , 2011, Cancer research.
[54] T. Jacks,et al. Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. , 2011, Cancer cell.
[55] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[56] Alberto Mantovani,et al. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. , 2010, Current opinion in immunology.
[57] Zlatko Trajanoski,et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. , 2010, Gastroenterology.
[58] M. Karin,et al. Immunity, Inflammation, and Cancer , 2010, Cell.
[59] Carsten Denkert,et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] M. Schwaiger,et al. TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. , 2008, Cancer cell.
[61] Lloyd J. Old,et al. Adaptive immunity maintains occult cancer in an equilibrium state , 2007, Nature.
[62] Robert D. Schreiber,et al. Interferons, immunity and cancer immunoediting , 2006, Nature Reviews Immunology.
[63] Eric J. Brown,et al. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor , 2005, Nature.
[64] R. Schreiber,et al. The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.
[65] R. Schreiber,et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.
[66] M. Burnet. Cancer—A Biological Approach , 1957, British medical journal.